After two successful clinical trials (Bachelez et al., 2019, 2021), the anti-IL36R antibody spesolimab was granted Food and Drug Administration Breakthrough Therapy Designation, leading to its recent approval for the treatment of GPP (Blair, 2022). The gene discussed is IL1RL2; the disease is psoriasis 14, pustular.